-
International Journal of Nephrology and Renovascular Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients
Review
(3514) Views (759) Full article downloads
Authors: P Dalal, G Shah, D Chhabra, et al
Published Date August 2010
Volume 2010:3 Pages 107 - 115
DOI: http://dx.doi.org/10.2147/IJNRD.S7044
P Dalal1, G Shah1, D Chhabra2, Lorenzo Gallon21Department of Medicine, Mount Sinai Hospital, Chicago; 2Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
Introduction: Several new medications are now available for immunosuppression in the kidney transplant field. Tacrolimus and mycophenolate mofetil were first introduced for immunosuppression in renal transplantation in the mid 1990s. Since then, the combination of tacrolimus and mycophenolate mofetil has been evaluated in numerous clinical trials. The outcomes of these trials have varied due to differences in induction and/or maintenance therapy, drug dosing and monitoring protocols, and study design. The aim of this review is to analyze the literature critically and to provide an overview of tacrolimus and mycophenolate mofetil combination therapy in renal transplantation.
Keywords: mycophenolate mofetil, tacrolimus, kidney transplantation, immunosuppression
Other articles by Dr Lorenzo Gallon
Readers of this article also read:
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Health literacy and health seeking behavior among older men in a middle-income nation
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Everolimus-eluting stents: update on current clinical studies
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
- Potential renovascular hypertension, space missions, and the role of magnesium
- The use of everolimus in renal-transplant patients
- Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate




